Enzon Pharmaceuticals, Inc. (ENZN) Widens Q3 Loss on Lighter Sales

November 3, 2011 4:37 PM EDT
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) reported Q3 EPS of ($0.19), versus ($0.14) reported last year. Revenue for the quarter came in at $10.44 million, versus $13.23 million reported last year.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings